Characteristics of the Iranian cohort studies included in the pooling project to define prediction models for CVD mortality
| TLGS1 | TLGS2 | ICS | GCS1 | GCS2 | ShECS | |
| Study baseline | 1999 | 2002 | 2001 | 2004 | 2010 | 2009 |
| Study population | Urban | Urban | Urban–Rural | Urban–Rural | Urban–Rural | Urban |
| Location | Tehran | Tehran | Isfahan, Najafabad, Arak | Gonbad, Kalaleh, Ag-Qala | Gonbad, Kalaleh, Ag-Qala | Shahroud |
| Age range, years | ≥3 | ≥3 | ≥35 | 40–75 | 45–80 | 40–64 |
| Baseline cohort size, n | 15 005 | 3550 | 6504 | 50 045 | 11 418* | 5190 |
| Rural population, % | – | – | 27.52 | 76.10 | 81.14 | – |
| Women, n (%) | 55.94 | 50.54 | 51.29 | 57.57 | 52.46 | 58.55 |
| Included in the current study† | 4809 | 927 | 5083 | 45 889 | 10 229 | 4583 |
| Women, n (%) | 2723 (56.6) | 449 (48.4) | 2605 (51.3) | 26 378 (57.5) | 5412 (52.9) | 2726 (59.5) |
| Median follow-up (IQR), years | 14.1 (13.6–14.6) | 9.6 (9.0–9.9) | 11.3 (10.9–12.3) | 9.1 (8.0–10.0) | 4.5 (3.9–5.0) | 5.0 (4.8–5.2) |
| No follow-up, n | 476 | 21 | 703 | 52 | 0 | 0‡ |
*This sample is a subgroup of GCS1.
† Participants aged 40–80 years and free of CVD at baseline were included in the current study.
‡Three hundred and forty-five individuals had no information of both CVD history at baseline and follow-up, so they were excluded as unknown CVD.
CVD, cardiovascular disease; GCS1, Golestan Cohort Study phase 1; GCS2, Golestan Cohort Study phase 2; ICS, Isfahan Cohort Study; ShECS, Shahroud Eye Cohort Study; TLGS1, Tehran Lipid and Glucose Study phase 1; TLGS2, Tehran Lipid and Glucose Study—new recruited individuals in phase 2.